Lilly Antibody Treatment Lands FDA Emergency Use Authorization
The U.S. Food and Drug Administration has granted an Emergency Use Authorization for a COVID-19 antibody therapy developed by Indianapolis-based Eli Lilly and Co. (NYSE: LLY). The treatment, known as bamlanivimab or LY-CoV555), is authorized for the treatment of mild-to-moderate COVID-19 in [点击 More>>>]